Is venetoclax appropriate for relapsed CLL patients?
From chemotherapy towards targeted therapies in CLL
Results of trial of vadastuximab talirine plus hypomethylating agents in AML
Predicting resistance to therapy in CLL
Highlights from EHA 2016 press briefings: Nivolumab, SGN-CD33A and hemophilia